- Home
- NRXP vs ATYR Comparison
NRXP vs ATYR Comparison
Compare NRXP & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 79.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NRXP | ATYR |
|---|---|---|
| Price | $2.28 | $0.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $30.67 | $8.75 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $242,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $847.91 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $0.64 |
| 52 Week High | $4.48 | $7.29 |
Technical Indicators
Market Signals| Indicator | NRXP | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 43.87 |
| Support Level | $2.00 | $0.66 |
| Resistance Level | $2.48 | $0.74 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 35.95 | 29.11 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.